Skip to main content
NewslettersWatchlist

Dare Bioscience Inc(DARE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.4299
Day High0.4899
Open:0.4300
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
TheNewswire.com
Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?
Globe Newswire
Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update
Globe Newswire
Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022
Globe Newswire
Daré Bioscience to Participate in Maxim Group Women’s Health Panel
Globe Newswire
Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
Globe Newswire
Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022
Globe Newswire
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
Globe Newswire
Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update
Globe Newswire
Daré Bioscience Announces NIH Grant Award
Globe Newswire
Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update
Business Wire
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
Globe Newswire
Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022
Globe Newswire
Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference
Globe Newswire
Daré Bioscience to Participate in Upcoming Conferences
Globe Newswire
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
Globe Newswire
Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update
Globe NewsWire
Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1
Globe NewsWire
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy
Globe NewsWire
Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference
Globe NewsWire
Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Globe NewsWire
Daré Bioscience to Participate in Panel Discussion at Women’s Health Innovation Summit
Globe NewsWire
Daré Bioscience to Present at the 13th European Congress on Menopause and Andropause
Globe NewsWire
Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update
Globe NewsWire
Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis
Globe NewsWire
Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021
Globe NewsWire
Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021
Globe NewsWire
Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive
Globe NewsWire
Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1
Globe NewsWire
Daré Bioscience to Present at 2021 BIO Digital
Globe NewsWire
Daré Bioscience Reports First Quarter 2021 Financial Results and Provides a Company Update
Globe NewsWire
Daré Bioscience to Host First Quarter 2021 Financial Results and Company Update Conference Call and Webcast on May 13, 2021
Globe NewsWire
Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

Profile

Dare Bioscience, Inc. is a healthcare company. It involved in the development and commercialization of products in women's reproductive health. Dare Bioscience, Inc., formerly known as Cerulean Pharma Inc., is based in SAN DIEGO.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.